Assessment and predictors of inappropriate dose of direct oral anticoagulants

Assessment and predictors of inappropriate dose of direct oral anticoagulants

Direct-Acting Oral Anticoagulants (DOACs) have revolutionized the management of Atrial Fibrillation (AF) and Venous Thromboembolism (VTE). However, recent audits reveal a significant burden of inappropriate dosages in the prescribing of direct-acting oral anticoagulants. Our aim is to identify the...

Full description

Bibliographic Details
Main Author:	Mosaad O. Almegren
Format:	Article
Language:	English
Published:	PAGEPress Publications 2024-01-01
Series:	Italian Journal of Medicine
Subjects:	Venous thromboembolism atrial fibrillation dabigatran rivaroxaban apixaban
Online Access:	https://www.italjmed.org/index.php/ijm/article/view/1679

Similar Items

Utilization and prescribing patterns of direct oral anticoagulants
by: Whitworth MM, et al.
Published: (2017-03-01)

NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
by: D. A. Napalkov, et al.
Published: (2015-09-01)

Factors associated with inappropriate reduced doses of non-vita-min K antagonist oral anticoagulants in patients with atrial fibrillation
by: V. A. Ionin, et al.
Published: (2021-10-01)

Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
by: B. A. Tatarsky, et al.
Published: (2022-11-01)

Efficacy and safety of new oral anticoagulants compared with warfarin in cardioembolic prophylaxis of patients with non valvular atrial fibrillation. More lights than shadows
by: Luca Masotti, et al.
Published: (2012-10-01)

Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation
by: Luca Masotti, et al.
Published: (2013-12-01)

Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true
by: Yu. A. Bunin, et al.
Published: (2016-09-01)

Prevention of recurrent deep-vein thrombosis
by: Andrew N Nicolaides
Published: (2019-01-01)

Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction
by: Z. D. Kobalava, et al.
Published: (2021-03-01)

SAFETY OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: A TWO-YEAR COHORT STUDY
by: A. V. Zhilenko, et al.
Published: (2017-07-01)

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT
by: E. L. Dolgova, et al.
Published: (2015-09-01)

Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions
by: V. A. Ionin, et al.
Published: (2021-05-01)

Direct oral anticoagulants and travel-related venous thromboembolism
by: Chamnanchanunt Supat, et al.
Published: (2018-11-01)

Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valve Replacement or Repair
by: Amgad Mentias, et al.
Published: (2022-09-01)

The treatment of venous thromboembolism with new oral anticoagulants
by: Davide Imberti
Published: (2013-12-01)

EFFICACY AND SAFETY OF THE ORAL ANTICOAGULANTS IN THE MANAGEMENT OF VENOUS THROMBOEMBOLISM: INDIRECT COMPARISON
by: V. I. Petrov, et al.
Published: (2016-12-01)

COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS
by: V. A. Sulimov, et al.
Published: (2015-09-01)

Old and new oral anticoagulants for secondary stroke prevention in atrial fibrillation
by: Tommaso Sacquegna, et al.
Published: (2015-12-01)

A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
by: Hyeongsoo Kim, et al.
Published: (2020-01-01)

Perioperative venous thromboembolic disease and the emerging role of the novel oral anticoagulants: An analysis of the implications for perioperative management
by: Martina Mookadam, et al.
Published: (2015-01-01)

Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
by: A. A. Zarudsky, et al.
Published: (2020-03-01)

The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality
by: B. A. Tatarsky, et al.
Published: (2020-05-01)

Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis
by: Attard LM, et al.
Published: (2022-10-01)

ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)

Practical issues in measuring the anticoagulant effect of direct oral anticoagulants
by: Dopsaj Violeta
Published: (2020-01-01)

Current approaches to periprocedural anticoagulation treatment in patients undergoing atrial fibrillation ablation
by: N. Z. Gasymova, et al.
Published: (2019-05-01)

PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS
by: A. А. Sokolova, et al.
Published: (2017-12-01)

Systematic errors in the choice of dose level of direct oral anticoagulants: urgency of an issue and approaches to its solution
by: S. R. Gilyarevskiy, et al.
Published: (2021-10-01)

Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants
by: S. R. Gilyarevsky, et al.
Published: (2023-07-01)

Left Atrial Thrombus in Atrial Fibrillation/Flutter Patients in Relation to Anticoagulation Strategy: LATTEE Registry
by: Agnieszka Kapłon-Cieślicka, et al.
Published: (2022-05-01)

Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective
by: Vidal Hector O, et al.
Published: (2011-07-01)

Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions
by: James S Kalus
Published: (2013-04-01)

New oral anticoagulants and cardiac safety: do we have a problem?
by: E. M. Nifontov
Published: (2018-04-01)

Physician perceptions and use of reduced‐dose direct oral anticoagulants for extended phase venous thromboembolism treatment
by: Danielle Groat, et al.
Published: (2022-05-01)

Pharmacogenetics of new oral anticoagulants
by: Bella A. Azimova, et al.
Published: (2023-04-01)

HOW NEW APPROACHES TO THE TREATMENT OF PULMONARY EMBOLISM AFFECT THE OUTCOME OF THE DISEASE?
by: M. Y. Gilyarov, et al.
Published: (2017-12-01)

Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions
by: Natalia A. Shnayder, et al.
Published: (2021-04-01)

Direct oral anticoagulants; a review for the non-specialist
by: Thilina Gunawardena
Published: (2021-11-01)

The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants
by: Jamshed Dalal, et al.
Published: (2015-12-01)

Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
by: Song AB, et al.
Published: (2019-06-01)